Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fasting conditions.s.

2025-524035-39-00 Protocol 1062/25 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 14 Jan 2026 · End 3 Feb 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 1062/25

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 32
Countries 1
Sites 1

Bioavailability study in healthy volunteers under fasting conditions.

Key facts

Sponsor
Laboratorios Cinfa S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
14 Jan 2026 → 3 Feb 2026
Decision date (initial)
2025-12-09
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Bioavailability study in healthy volunteers under fasting conditions.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Laboratorios Cinfa S.A.

Sponsor organisation
Laboratorios Cinfa S.A.
Address
Poligono Industrial Areta Carretera Olaz Chipi 10
City
Huarte
Postcode
31620
Country
Spain

Scientific contact point

Organisation
Laboratorios Cinfa S.A.
Contact name
Rubén Rubén Estepa Sanz

Public contact point

Organisation
Laboratorios Cinfa S.A.
Contact name
Rubén Rubén Estepa Sanz

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 32 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
Clinical Unit, Prazska 1486/18c, Hostivar, Prague

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2026-01-14 2026-02-03 2026-01-14 2026-01-24

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-11-07 Czechia Acceptable
2025-12-05
2025-12-09
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-12-15 Czechia Acceptable
2025-12-05
2025-12-15